SG11201600076WA - LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME - Google Patents

LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME

Info

Publication number
SG11201600076WA
SG11201600076WA SG11201600076WA SG11201600076WA SG11201600076WA SG 11201600076W A SG11201600076W A SG 11201600076WA SG 11201600076W A SG11201600076W A SG 11201600076WA SG 11201600076W A SG11201600076W A SG 11201600076WA SG 11201600076W A SG11201600076W A SG 11201600076WA
Authority
SG
Singapore
Prior art keywords
sirna
double
preventing
composition
same
Prior art date
Application number
SG11201600076WA
Inventor
Jeiwook Chae
Han Oh Park
Pyoung Oh Yoon
Boram Han
Han-Na Kim
Sung-Il Yun
Jun Hong Park
Youngho Ko
Gi-Eun Choi
Junsoo Jung
Jae Eun Kim
Original Assignee
Bioneer Corp
Sanofi Aventis Korea Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioneer Corp, Sanofi Aventis Korea Co Ltd filed Critical Bioneer Corp
Publication of SG11201600076WA publication Critical patent/SG11201600076WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201600076WA 2013-07-09 2014-07-09 LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME SG11201600076WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20130080579A KR20150006742A (en) 2013-07-09 2013-07-09 Liver cancer related genes-specific siRNA, double-stranded oligo RNA molecules comprising the siRNA, and composition for the prevention or treatment of cancer comprising the same
PCT/KR2014/006145 WO2015005669A1 (en) 2013-07-09 2014-07-09 LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME

Publications (1)

Publication Number Publication Date
SG11201600076WA true SG11201600076WA (en) 2016-02-26

Family

ID=52280271

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201600076WA SG11201600076WA (en) 2013-07-09 2014-07-09 LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME

Country Status (7)

Country Link
US (1) US20160168573A1 (en)
EP (1) EP3019611A4 (en)
JP (1) JP2016531563A (en)
KR (1) KR20150006742A (en)
CN (1) CN105765069A (en)
SG (1) SG11201600076WA (en)
WO (1) WO2015005669A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210093654A1 (en) * 2017-07-28 2021-04-01 Lemonex Inc. Pharmaceutical composition for preventing or treating liver cancer
CN110964816A (en) * 2019-11-20 2020-04-07 深圳市鲲鹏未来科技有限公司 Solution containing blood-stable nanoparticles, preparation method thereof and detection method of miRNA marker
CN111189808B (en) * 2019-12-25 2022-12-06 宁夏医科大学总医院 Screening method of specific protein molecular marker related to liver injury and hepatocyte apoptosis
CN111596059A (en) * 2020-05-19 2020-08-28 上海长海医院 Application of Gankyrin protein as novel molecular marker in prostate cancer prognosis evaluation
KR102329524B1 (en) * 2021-08-06 2021-11-23 주식회사 네오나 Composition for preventing or treating of liver cancer comprising modified rt-let7 as an active ingredient
WO2023013818A1 (en) * 2021-08-06 2023-02-09 주식회사 네오나 Composition for prevention or treatment of liver cancer comprising modified rt-let7 as active ingredient

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2159626C (en) * 1993-04-02 2001-10-02 Lingna Li Method for delivering beneficial compositions to hair follicles
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
EP1812494A1 (en) * 2004-09-29 2007-08-01 Alza Corporation Microparticles and nanoparticles containing a lipopolymer
CA2675834A1 (en) * 2007-01-16 2008-07-24 Proteologics, Ltd. Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors
KR101224828B1 (en) * 2009-05-14 2013-01-22 (주)바이오니아 SiRNA conjugate and preparing method thereof
EP2496268A4 (en) * 2009-11-06 2013-06-19 Univ Chung Ang Ind Nanoparticle-based gene delivery systems
ES2899043T3 (en) * 2011-12-15 2022-03-09 Bioneer Corp Novel oligonucleotide conjugates and their use

Also Published As

Publication number Publication date
WO2015005669A1 (en) 2015-01-15
JP2016531563A (en) 2016-10-13
CN105765069A (en) 2016-07-13
EP3019611A4 (en) 2017-06-14
KR20150006742A (en) 2015-01-19
US20160168573A1 (en) 2016-06-16
EP3019611A1 (en) 2016-05-18

Similar Documents

Publication Publication Date Title
EP3326661B8 (en) Bio-ink composition having improved physical and biological properties
EP3019612A4 (en) LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME
HK1215378A1 (en) Pharmaceutical composition, methods for treating and uses thereof
IL243752B (en) Multispecific antibodies, compositions comprising same and uses thereof
EP2861256A4 (en) Compositions for treating cancer and methods for making the same
IL245281A0 (en) Methods and compositions for treating cancer
BR112015001838A2 (en) efflux inhibitor compositions and treatment methods using the same.
EP3018209A4 (en) Respiratory disease-related gene specific sirna, double-helical oligo rna structure containing sirna, compositon containing same for preventing or treating respiratory disease
EP2818483A4 (en) Medicinal composition for treating and/or preventing cancer
EP3074391A4 (en) Rna polymerase i inhibitors and uses thereof
EP3085784A4 (en) Nucleic acid inducing rna interference modified for preventing off-target, and use thereof
PT3272874T (en) Reagent composition for biosensor and biosensor having the same
SG11201600076WA (en) LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME
IL277261A (en) Small molecules against cancer
EP3052510A4 (en) Methods and compositions for treating and/or preventing mucositis
EP3085380A4 (en) Composition for treating prostate cancer
IL241823B (en) C. novyi containing compositions and uses thereof in treating solid tumors
EP2822998A4 (en) Compatibilized composition, method for the formation thereof, and article comprising same
ZA202001649B (en) Rna molecules
EP2981554A4 (en) Methods and compositions for treating and preventing disease associated with avb8 integrin
EP3052122A4 (en) Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma
BR112015002729A2 (en) coating composition, article, and method.
EP2887942A4 (en) Compositions and methods for treating or preventing anthracycline induced cardiotoxicity
EP2836551A4 (en) Compatibilized composition, method for the formation thereof, and article comprising same
EP3363461A4 (en) Anti-cd43 antibody and use thereof for cancer treatment